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ELMO1 protects renal structure 
and ultrafiltration in kidney 
development and under diabetic 
conditions
Krishna Rakesh Sharma1,*, Karl Heckler1,*, Sandra J. Stoll1,2, Jan-Luuk Hillebrands3, 
Katharina Kynast4, Esther Herpel4,5, Stefan Porubsky6, Marlies Elger7, Boris Hadaschik8, 
Karen Bieback9, Hans-Peter Hammes10, Peter P. Nawroth11 & Jens Kroll1,2
Engulfment and cell motility 1 (ELMO1) functions as a guanine exchange factor for Rac1 and was 
recently found to protect endothelial cells from apoptosis. Genome wide association studies suggest 
that polymorphisms within human elmo1 act as a potential contributing factor for the development 
of diabetic nephropathy. Yet, the function of ELMO1 with respect to the glomerulus and how this 
protein contributes to renal pathology was unknown. Thus, this study aimed to identify the role 
played by ELMO1 in renal development in zebrafish, under hyperglycaemic conditions, and in diabetic 
nephropathy patients. In zebrafish, hyperglycaemia did not alter renal ELMO1 expression. However, 
hyperglycaemia leads to pathophysiological and functional alterations within the pronephros, 
which could be rescued via ELMO1 overexpression. Zebrafish ELMO1 crispants exhibited a renal 
pathophysiology due to increased apoptosis which could be rescued by the inhibition of apoptosis. 
In human samples, immunohistochemical staining of ELMO1 in nondiabetic, diabetic and polycystic 
kidneys localized ELMO1 in glomerular podocytes and in the tubules. However, ELMO1 was not 
specifically or distinctly regulated under either one of the disease conditions. Collectively, these results 
highlight ELMO1 as an important factor for glomerular protection and renal cell survival via decreasing 
apoptosis, especially under diabetic conditions.
Diabetes mellitus is known to cause several micro- and macrovascular complications within patients world-
wide. Diabetic nephropathy is a very concerning microvascular complication of diabetes mellitus, whose global 
incidence is on the rise, rapidly1,2. It has been established that diabetic nephropathy eventually progresses into 
end-stage renal disease and is the leading cause for renal replacement therapy in developed countries3. To treat 
patients suffering from diabetic nephropathy, it is important to understand the underlying mechanisms that lead 
to the pathology of the disease. It is known that diabetic nephropathy is predominantly associated with increasing 
proteinuria, which is characterized by the expulsion of proteins such as albumin in the urine, as well as a reduced 
blood-filtration rate. Diabetes induced albuminuria is initiated primarily due to the loss and/or dysfunction of 
podocytes4. Remarkably, the progression of diabetic nephropathy has been shown to correlate with the loss of 
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podocytes in patients suffering from the microvascular complication5. Hyperglycaemia is also known to induce 
and subsequently increase apoptosis within renal glomerular cells, albeit via the activation of endothelial throm-
bomodulin–protein C system, which contributes to the pathogenesis of diabetic nephropathy6. Hence, this study 
evidentially demonstrates, that hyperglycaemia induces an increase in apoptosis within the human glomerular 
endothelial cells and podocytes. However, a better insight must be obtained with respect to the detrimental effects 
of increased apoptosis in the renal glomerular cells and the subsequent onset of diabetic nephropathy.
Genome wide association studies (GWAS) indicate that polymorphisms in a multitude of genes were asso-
ciated with the heightened incidence of nephropathy in diabetic patients7. To develop new preventative and 
therapeutic strategies, these polymorphisms need to be studied carefully. Particularly, single nucleotide polymor-
phisms (SNPs) in human elmo1 are strongly suggested to be a potential contributing factor for the development of 
diabetic nephropathy, in various global populations8–11. The ELMO1/DOCK180 complex functions as a guanine 
nucleotide exchange factor for the small GTPase Rac1, thereby regulating cell migration12. ELMO1 is expressed 
in the vasculature in zebrafish and loss-of-function experiments identified an important role for ELMO1 in early 
developmental vascular processes13. Recently, ELMO1 was shown to protect endothelial cells from apoptosis via 
activation of the Rac1/PAK/AKT signalling cascade in vitro and in vivo14. ELMO1 has also been implicated in 
the development of ciliopathy-related phenotypes in zebrafish, by regulating Ezrin phosphorylation15. However, 
the functional role of ELMO1 in human and zebrafish kidneys, with respect to diabetic nephropathy, is currently 
unknown and is in the need to be established.
The zebrafish is a versatile model organism used to carry out research on various biomedical fields, including 
diabetes induced complications within the vasculature16. The renal system within a zebrafish embryo consists of a 
pronephros which, although simple in structure, functions to maintain homeostatic balance of ion and metabolite 
concentrations, and removal of toxic substances in the blood, similar to the human nephron17. Thus, this study 
aims to establish the functional role of ELMO1 in the zebrafish pronephric glomerulus, under hyperglycaemic 
conditions. We found that, in the zebrafish pronephros, ELMO1 protects the glomerulus from apoptosis and from 
hyperglycaemia induced damage. These findings are also supported by immunohistochemical analysis of human 
kidney sections, obtained from patients suffering from prolonged hyperglycaemia, due to diabetes mellitus type 2.
Results
Human diabetic patients and hyperglycaemic zebrafish illustrate no change in ELMO1 
expression in the kidney. ELMO1 expression was analysed for potential changes within human kid-
ney sections received from nondiabetic, diabetic (type 2) and polycystic kidney disease patients (Fig. 1 and 
Supplementary Figure 1). Glomeruli in nondiabetic kidneys also showed ELMO1 positive reactivity in podo-
cytes (Fig. 1D,E), but expression was almost absent in glomerular endothelial cells (Supplementary Figure 2D,E). 
It was also observed, that under nondiabetic conditions, ELMO1 was also expressed within the tubules. 
Remarkably, ELMO1 expression remained unchanged within the kidney of patients suffering from type 2 dia-
betes, although the renal expressional pattern of ELMO1 was similar to that of nondiabetic patients (Fig. 1I–K; 
Supplementary Figures 2I,J). Unaltered expression was also observed in patients suffering from polycystic kidney 
disease (Supplementary Figure 1C). Thus, histological results indicate that ELMO1 is equally expressed in differ-
ent kidney diseases and not differentially regulated, due to a specific pathological condition.
To induce hyperglycaemia in zebrafish embryos, the morpholino technology was employed to knockdown 
PDX1 transiently16. Subsequently, we collected pronephric cells from the Tg(wt1b:EGFP) zebrafish line (Fig. 2A) 
subjected to hyperglycaemia and performed a real-time quantitative PCR, to assess expressional changes of 
ELMO1 within the renal system of the zebrafish embryo under normo- and hyperglycaemic conditions. It is 
important to note that only podocytes are labelled with EGFP within the glomerulus in the Tg(wt1b:EGFP) 
zebrafish embryos18. No significant change in ELMO1 expression was observed (Fig. 2B,C) within the pronephros 
of hyperglycaemic embryos as compared to the control. These findings indicate that the data on the zebrafish 
embryos is relatable to patient data, where ELMO1 expression remains unaltered in diabetic patients (Fig. 1).
Hyperglycaemia and ELMO1 CRISPR injection lead to adverse changes in the zebrafish 
pronephros. We next aimed to assess the role of ELMO1 in renal structural and functional development, 
under hyperglycaemic conditions. Consequently, effects of PDX1 knockdown and knockout of ELMO1 were 
analysed with respect to the zebrafish pronephros (Fig. 3). As compared to the control (Fig. 3A), the PDX1 mor-
phants, at 48 hpf, exhibited an enlarged glomerulus, where the width was significantly increased from 60 μ m in 
the controls to 75 μ m in PDX1 morphants (Fig. 3B,E). The neck of the PDX1 morphants was greatly shortened to 
50 μ m in 4 ng injected PDX1 morphants and 37 μ m in 6 ng injected PDX1 morphants, as compared to a length of 
63 μ m in the controls (Fig. 3B,F).
CRISPR/Cas9 mediated ELMO1 knockout (Supplementary Figure 3) was carried out and embryos aged 
48 hpf were studied for renal phenotypes. Similar to hyperglycaemia induced changes, ELMO1 crispants exhib-
ited alterations in the zebrafish pronephric structure. As compared to the control (Fig. 3C), ELMO1 crispants 
displayed a significant increase in width (from 60 μ m in controls to 76 μ m in the ELMO1 crispants) and strong 
reduction of the neck (from 80 μ m in controls to 40 μ m in the ELMO1 crispants) (Fig. 3D,G,H). To evaluate 
hyperglycaemia and ELMO1 knockout effects on renal functionality, we assessed pronephric ultrafiltration 
(Supplementary Figure 4). The assay to determine changes in the functionality of the zebrafish pronephros has 
already been established19. Upon heart injection of the 70 kDa Texas-Red® dextran, a significantly increased 
loss of heart fluorescence over time, in PDX1 morphants and the ELMO1 crispants, was observed as compared 
to their controls (Fig. 3I). This indicates an adversity in the ultrafiltration, in both the hyperglycaemic fish and 
ELMO1 crispants. Thus, hyperglycaemic conditions and ELMO1 knockout, not only alter pronephric structure, 
but also adversely affect the function of the renal system, within zebrafish embryos.
www.nature.com/scientificreports/
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Figure 1. Human glomerular expression of ELMO1 is seen specifically within podocytes and remains 
unaltered in diabetic patients as compared to nondiabetic patients. ELMO1 expression within the glomerulus 
appears to be present specifically in podocytes in human control and diabetic patients. (A–E) Illustrate a glomerulus 
from a control patient. (B) Indicates ELMO1 expression, highly present in the tubules and to lesser extent within the 
glomerulus. (C) Illustrates nephrin (podocyte marker) expression in green. A merger of panels, (D) displays that 
ELMO1 expression within the glomerulus partially co-localises with nephrin, indicating that ELMO1 expression 
is of podocyte origin, within the renal structure. This is further emphasised in panel (E) where ELMO1 expression 
specifically in the glomerulus is indicated with white arrow head. Cytosolic ELMO1 expression within podocytes 
near the nuclei (blue), surrounded by extracellular nephrin staining is indicated in (E) with a white arrow. Similarly, 
(F–J) illustrate a glomerulus from a type 2 diabetic patient, displaying similar ELMO1 and nephrin expression 
patterns. The white dotted line in (I) illustrates a scale bar of 50 μ m. (K) Illustrates quantified ELMO1 expression 
within renal glomerulus and the proximal tubules, in diabetic and nondiabetic patients (eight different glomeruli 
and proximal tubules were analysed over 5 patients per group). The graphs indicate no significant difference in 
ELMO1 expression under diabetic conditions as compared to the control patients (n = 5).
www.nature.com/scientificreports/
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Hyperglycaemia induced pronephric structural and functional alterations within zebrafish 
embryos can be significantly rescued via ELMO1 overexpression. As hyperglycaemia and knock-
out of ELMO1 have similar detrimental effects on the zebrafish pronephric structure and function, we aimed to 
establish whether overexpression of ELMO1, could rescue hyperglycaemic renal alterations as shown in Fig. 3. 
Overexpression of ELMO113,14 (Supplementary Figure 6) could beneficially restore the compromised pronephric 
structure within PDX1 morphants (Fig. 4A–D). The structural changes represented by glomerular enlargement 
and reduced pronephric neck length in PDX1 morphants (Fig. 4B,E,F) were almost entirely normalized upon the 
co-injection of ELMO1 mRNA. Similarly, increased clearance of the 70 kDa Texas-Red® dextran within PDX1 
morphants was decreased to levels corresponding to controls, upon ELMO1 overexpression (Fig. 4G). Thus, 
under hyperglycaemic conditions, overexpression of ELMO1 was found to rescue the altered renal structure and 
function within zebrafish embryos.
Podocyte foot processes are detrimentally affected in PDX1 morphants and ELMO1 crispants, 
altering the glomerular filtration barrier. Since the renal filtration barrier is drastically altered in a dia-
betic nephropathy setting4, we aimed to determine if at an electron microscopic level, PDX1 morphants and 
ELMO1 crispants were affected, especially with respect to podocyte structure and the formation of the ultrafiltra-
tion barrier. Consequently, we found that PDX1 morphants (48 hpf) display a highly dystrophic filtration barrier 
as compared to their controls (Fig. 5A,C), where the podocyte structure contributed to a highly under-developed 
filtration barrier. Foot processes between adjacent podocytes did not interdigitate appropriately and urinary space 
was absent. ELMO1 crispants (48 hpf) also exhibited inappropriate podocyte development and filtration barrier, 
as compared to the control (Fig. 5B,D). Specifically, in ELMO1 crispants foot processes did not develop and inter-
digitate to form the filteration barrier and podocytes appeared unable to filter the blood plasma (Fig. 5D). Thus, 
it is further established that, even at a subcellular level, hyperglycaemia and ELMO1 CRISPR injections lead to 
podocyte structural adversities.
Pancaspase inhibitor, zVAD-fmk, treatment can restore altered structural and functional 
changes in ELMO1 CRISPR injected embryos. Recently, ELMO1 has been established to protect 
endothelial cells from apoptosis during angiogenesis14. It was hypothesized that a similar function is being 
Figure 2. Expression of ELMO1 is observed within the zebrafish pronephros but remains unaltered under 
hyperglycaemic conditions as compared to normoglycaemic fish. (A) Illustrates the position of the pronephros 
in a Tg(wt1b:EGFP) embryo (48 hpf), visible from the dorsal view. The renal structure is composed of two 
tubules that are fused to form a single glomerulus (white arrow) via a neck (white hashtag). Both the scale bars 
represent 200 μ m. (B) No change in relative ELMO1 expression was observed within the zebrafish pronephros 
under hyperglycaemic conditions (4 ng morpholino injection against insulin promotor factor 1, PDX1). Co. Mo. 
indicates 4 ng control morpholino. Pronephric cells were isolated for mRNA extraction via FACS sorting from 
Tg(wt1b:EGFP) embryos for cDNA synthesis and subsequent real-time qPCR analysis. (C) tabulates the mean 
Cp (crossing point of the amplifying fluorescence exceeding the background fluorescence) values of ELMO1 
(target) and β -actin 1 (reference) expression.
www.nature.com/scientificreports/
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performed by the protein in the renal system. zVAD-fmk has been previously utilized as an apoptotic inhibitory 
compound on zebrafish embryos20. Anti-apoptotic treatment of zebrafish embryos was carried out at the age of 
Figure 3. Zebrafish pronephric structure and function are adversely affected by hyperglycaemia and 
upon CRISPR mediated ELMO1 knockout. As compared to the zebrafish pronephros at 48 hpf in control 
morphants, Co. Mo., (A) hyperglycaemic PDX1 morphants, PDX1 Mo., (B) display an enlarged glomerulus 
(white arrow head) and highly shortened pronephric neck (white asterix). (C) Control crispanst (Co. CRISPR) 
display a normal glomerulus. (D) In contrast, ELMO1 crispants, (ELMO1 CRISPR), show an enlarged 
glomerulus (white arrow head) and a highly shortened pronephric neck (white asterix). (E–H) The altered 
structure in morphants and crispants has been quantified in n = 40 embryos for each condition. (I) Displays 
the quantified elevated loss of fluorescence in ELMO1 crispants (n = 38) and PDX1 morphants (n = 26) as 
compared to their respective controls (Co. CRISPR, n = 39 and Co. Mo., n = 30). The white line in image  
(D) represents the scale bar corresponding to 200 μ m.
www.nature.com/scientificreports/
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Figure 4. Over-expression of ELMO1 rescues the renal structural and functional phenotype caused  
due to hyperglycaemia. As compared to the zebrafish pronephros at 48 hpf in control morphants, Co. Mo.,  
(A) hyperglycaemic PDX1 morphants, PDX1 Mo. (4 ng), (B) display an enlarged glomerulus (white arrow head) 
and a highly shortened pronephric neck (white asterix). (C) Overexpression of ELMO1 has no detrimental 
effects on the zebrafish pronephros, however, (D) overexpression of ELMO1 in PDX1 morphants significantly 
rescues pronephric phenotype. (E,F) The altered structure in PDX1 morphants and their subsequent rescue 
with ELMO1 overexpression is quantified in n = 40 embryos, for each condition. (G) Displays the quantified 
elevated loss of fluorescence in PDX1 morphants (n = 23) and the significant increase in fluorescence within 
hyperglycaemic fish upon ELMO1 overexpression (Double Co. Mo. and mRNA, n = 23; ELMO1 mRNA, n = 23; 
and PDX1 Mo. with ELMO1 mRNA, n = 23).
www.nature.com/scientificreports/
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24 hpf for 24 hours, in order to observe any changes in the pronephros (Fig. 6). It was observed that upon treat-
ment with zVAD-fmk, ELMO1 crispants showed a significant rescue of pronephric structure as compared to 
those embryos without treatment (Fig. 6A,B,D,E,G,H). The zVAD-fmk treatment reduced significantly the width 
of the enlarged glomerulus from 81 μ m to 60 μ m in length, and restored the length of the pronephric neck of the 
compromised ELMO1 embryos from 18 μ m to 75 μ m in length, which are comparable to the control embryos 
(Fig. 6G,H). Ultrafiltration was also analysed in the ELMO1 crispants upon zVAD-fmk treatment. zVAD-fmk 
treatment of the ELMO1 CRISPR injected embryos also considerably rescued the fluorescence loss from the 
heart as compared to those ELMO1 crispants without treatment (Fig. 6I). Interestingly, it was found that the 
pronephros in PDX1 morphants displayed no signs of improvement in structural and functional integrity, upon 
pancaspase inhibitor treatment (Fig. 6C,F,G,H,J). Thus, the loss of ELMO1 causes structural and functional phe-
notype within the zebrafish embryos due to an increase of apoptosis, which can be rescued upon pancaspase 
inhibitor treatment. However, hyperglycaemia induced pronephric changes within the zebrafish embryos cannot 
be rescued with zVAD-fmk treatment alone, owing to the probable activation of other detrimental mechanisms21.
Finally, we aimed to establish if ELMO1 knockout indeed causes an increased incidence of apoptotic cells. The 
TUNEL assay was employed on ELMO1 crispant embryos, in order to visualize any significant increase in apop-
tosis universally and especially within the pronephros (Fig. 7). ELMO1 crispants displayed a significantly much 
higher incidence of apoptotic cells as compared to their controls, at 48 hpf (red dots, Fig. 7A,B). This increase 
in number of apoptotic cells is not only observed throughout the embryos, but also within the pronephros in 
the ELMO1 crispants as compared to their controls (Fig. 7E). This data has been further demonstrated with an 
activated Caspase3 assay (Supplementary Figure 7). Furthermore, zVADfmk treatment of ELMO1 crispants not 
only restored pronephric structural adversities but also drastically reduced the incidence of apoptotic cells within 
these crispants (Fig. 7D,E). Hyperglycaemia did not lead to an increase in apoptotic cells within the pronephros 
(Fig. 7C,E). Thus, it is evident that ELMO1 knockout in zebrafish embryos leads to an increase in apoptosis within 
the entire organism, and particularly within the renal system.
Discussion
In this study, we have established an important role of ELMO1 in renal function, under hyperglycaemic condi-
tions, within the zebrafish and successfully translated our finding to the pathogenesis of human diabetic nephrop-
athy (Fig. 8). ELMO1 not only shields endothelial cells from apoptosis14, but also functions to protect glomerular 
cells from the phenomenon, under high glucose conditions. Hyperglycaemic conditions in zebrafish embryos 
caused by PDX1 knockdown16, do not induce ELMO1 expression within the pronephros. This coincides with 
our data from type 2 diabetic patients, where no change in ELMO1 expression was observed within the kidney, 
compared to nondiabetic and polycystic kidneys, respectively. Thus, our study suggests that the work performed 
Figure 5. Knockdown of PDX1 and knockout of ELMO1 causes alterations in podocytic structure within 
zebrafish embryos aged 48 hpf. (A,B) Podocytes (P) in Co. Mo. and Co. CRISPR zebrafish embryos aged 
48 hpf are well developed and have well defined foot processes that interdigitate amongst themselves to form 
functional filtration barriers (white arrow heads). (C) Upon PDX1 knockdown, complete distrophy of podocyte 
foot processes is observed. (D) Upon ELMO1 knockout, foot processes are immature and are unable to 
interdigitate to form an appropriate filteration barrier. The white line indicates the scale bar corresponding to  
1 μ m length. Number of embryos analysed per sample group were 10.
www.nature.com/scientificreports/
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Figure 6. Compromised pronephric structure and ultrafiltration in ELMO1 crispants, but not in 
PDX1 morphants, can be beneficially reversed upon treatment with pancaspase inhibitor, zVAD-fmk. 
Upon treatment with zVAD-fmk (300 μ M), pronephric structural defects in ELMO1 crispants at 48 hpf, are 
significantly restored to normalcy (A,B,D,E); n = 47 for each condition). The pancaspase inhibitor causes no 
adversity in the control embryos at 48 hpf (D). However, no significant restoration in pronephric structure is 
observed with zVAD-fmk treatment of PDX1 morphants, at the same age (C,F); n = 47 for both conditions). 
The white line in image (F) represents the scale bar corresponding to 200 μ m. The significant restoration of 
the glomerular width and neck via zVAD-fmk treatment in ELMO1 crispants as well as the lack of rescue in 
PDX1 morphants are quantified in graphs (G,H). Altered ultrafiltration in ELMO1 crispants is also improved 
significantly upon treatment with zVAD-fmk as seen in graph (I) but not in PDX1 morphants, as observed in 
(J) The n values for each sample set used for the functional assay are as follows: Co. CRISPR (22), Co. CRISPR 
with zVAD-fmk (23), ELMO1 CRISPR (22), ELMO1 CRISPR with zVAD-fmk (17), Co. Mo. (23), Co. Mo. with 
zVAD-fmk (23), PDX1 Mo. (26) and PDX1 Mo. with zVAD-fmk (22).
www.nature.com/scientificreports/
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on zebrafish embryos, can be translated to a clinical setting, where ELMO1 could protect the diseased kidney 
from increased apoptosis, irrespective of the underlying renal disease. Overexpression of ELMO1 within mam-
malian (rat) glomeruli has been previously linked to extracellular matrix protein accumulation under diabetic 
conditions, which is predicted to be a detrimental cause, leading to the pathogenesis of diabetic nephropathy11. 
However, several GWAS studies have indicated SNPs within the elmo1 gene relate to the susceptibility of patients 
suffering from diabetes to develop nephropathy, in various human populations8–10. These studies thus strongly 
indicate that mutations within the elmo1 gene may lead to pathogenesis of DN, thereby suggesting a protective 
function of this protein concerning the disorder. In accordance with the GWAS indication, we have established 
that overexpression of ELMO1 actually helps to protect renal structure from pathogenesis under hyperglycae-
mia. PDX1 knockdown causes similar detrimental alterations within the pronephric structure and function in 
zebrafish embryos, as observed within the pronephros of ELMO1 crispants. Furthermore, adversities within the 
renal structure of the zebrafish PDX1 morphants are significantly restored upon simultaneous overexpression 
of ELMO1. These findings lead to the conclusion that the increase in ELMO1 expression would be a protective 
Figure 7. ELMO1 knockout, but not hyperglycaemia, causes an increase in apoptotic cells within the 
zebrafish embryo as well as the pronephros, which can be rescued with pancaspase inhibitor, zVAD-fmk. 
(A) TUNEL assay was carried out on Co. CRISPR injected Tg(wt1b:EGFP) embryos at 48 hpf. The embryos 
showed no incidence of apoptosizing cells (indicated with the red spots) within the renal structure. (B) ELMO1 
CRISPR injected embryos showed a strong incidence of apoptosizing cells (red spots) universally as well as 
within the renal structure. (C) Indicated that hyperglycaemic embryos do not display increased apoptosis 
within the pronephros and (D) indicates that ELMO1 crispants displayed normalized renal structure and a 
drastic reduction of apoptosis, upon zVAD-fmk treatment, which is quantified in the graph. (E) The white line 
in (D) indicates a scale bar representing 100 μ m, the white arrow head indicated an enlarged glomerulus and 
the white asterisk illustrates shortening of the glomerular neck of the ELMO1 crispants as compared to the 
control. The white dotted circle encloses the glomerulus of the zebrafish pronephros. The number of embryos 
per condition analysed are 11.
www.nature.com/scientificreports/
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response of the pronephros to try and compensate against the harmful effects of the potentially damaging hyper-
glycaemia. To additionally strengthen this inference, ELMO1 knockout was found to be damaging to the zebrafish 
pronephric structure and function.
It is known previously that podocyte-specific deletion of Rac1 in mice, a protein activated by ELMO1 and 
Dock180 interaction, causes foot process effacement of these cells; but only leads to loss of podocytes under 
hyperglycaemic conditions22. Since ELMO1, the upstream regulator of Rac1, is associated with endothelial cell 
protection against apoptosis and with pathogenesis of DN, we predicted that ELMO1 plays the same survival role 
in the renal system subjected to physiological and hyperglycaemic conditions. Further investigation of ELMO1 
crispants displayed a significantly higher incidence of apoptotic cells within the whole embryo and especially 
within the pronephric structure, which we suggested to be the cause of structural and functional renal adversities. 
To confirm this hypothesis, treatment of ELMO1 crispants with the pancaspase inhibitor, zVAD-fmk, showed 
restoration of the renal disruptions, both structural and functional. Therefore, it is evident that ELMO1 protects 
renal cells from increased apoptosis within zebrafish embryos. Thus, we expect that an upregulation of ELMO1 
in the diabetic patients would likely protect the nephron from increased apoptosis, ultimately delaying the onset 
of diabetic nephropathy.
To ensure the relevance of our research, it was essential to transfer our findings in the zebrafish embryos to 
human patient data. Hence, kidney sections from nondiabetic, diabetic and polycystic kidney disease patients 
were tested for ELMO1 expression. We found that these patients, that we analysed, displayed an unaltered expres-
sion of ELMO1 within the renal parenchyma. This is in accordance with our research conducted on zebrafish 
embryos, but is in contrast to a recent published study which suggested that low ELMO1 expression prevents dia-
betic nephropathy development in mice23. It is common knowledge that no animal model completely adheres to 
the pathogenic mechanisms of human diabetic nephropathy. For example, mice with different background strains 
have variable susceptibility to developing diabetic nephropathy. Additionally, all criteria for diabetic nephropa-
thy such as renal histolopathology and abnormal glomerular filtration rate are not completely relatable to mice 
models of diabetic nephropathy24,25. Thus, keeping this discrepancy of translatable murine data to human diabetic 
nephropathy in mind, a need for a new animal model is evident. Our data reinstates the relevance of zebrafish as 
a versatile animal model in basic diabetes research26. The zebrafish is known for its ease to work with, low mainte-
nance costs and high throughput. Our study further displays that the zebrafish is a valuable model not only to test 
Figure 8. Model of the functional role played by ELMO1 in the development of nephropathy under 
diabetic conditions. (A) ELMO1 plays a protective function for the renal system by safe guarding the organ 
from apoptosis, under physiological conditions. (B) In renal pathology, failure in increased ELMO1 expression 
is unable to cope with the disease induced apoptosis, which eventually leads to nephropathic alterations.
www.nature.com/scientificreports/
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an implicated protein in diabetic nephropathy but also to understand the underlying mechanisms of the protein 
within the renal system; establish possible treatments, and translate these finding to the human setting.
In conclusion, upregulation of ELMO1 is advantageous for renal cells in zebrafish, especially under unfa-
vourable hyperglycaemic conditions, which has been clearly established in the present study. Future prospects 
should thus focus on the induction of ELMO1 in diabetic conditions, in order to compensate for unfavorable 
effects of hyperglycaemia on the renal structure, contributing to diabetic nephropathy. Our findings clearly show 
that ELMO1 protects the renal system under hyperglycaemic conditions, via the reduction of apoptosis, within 
zebrafish embryos. The research is further translated in human patients suffering from long term hyperglycaemia 
leading to development of nephropathy.
Methods
Research design and methods. Zebrafish lines and husbandry. All experimental procedures on animals 
were approved by the local government authority, Regierungspräsidium Karlsruhe (license no.: 35-9185.81/G-
98/15) and carried out in accordance with the approved guidelines. Embryos of the lines tg(fli1:EGFP)27 and 
Tg(wt1b:EGFP)18 were raised and staged as previously described28. Embryos were kept in E3 medium (5 mM 
NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 5–10% methylene blue) at 28.5 °C with 0.003% 1-phenyl-2-thiourea (Sigma) 
to suppress pigmentation.
Inhibitors, antibodies and reagents. Goat anti-actin (1:1000) (Santa Cruz Biotechnology), goat anti- ELMO1 
(1:200) (Everest Biotechnology) were used for Western blotting. Immunohistochemistry (IHC) was done with 
a polyclonal rabbit anti-ELMO1 antibody (1:20), and rabbit anti-podocin antibody (1:400) (Sigma-Aldrich). 
CONFIRM anti-CD34 (QBEnd/10) Primary Antibody (mouse, 1:25) was used as an endothelial marker in 
IHC stainings (Ventana Medical Systems). Human nephrin antibody (Sheep polyclonal; R&D systems) (1:20) 
and, human CD34 (mouse monoclonal; ThermoFischer) (1:40) were used to stain human kindey sections for 
immune-fluoro-histochemistry. Secondary antibodies (Molecular Probes; Life Technologies) used were as fol-
lows: Alexa Fluor 546 goat anti-rabbit (for ELMO1 detection; 1:400); Alexa Fluor 488 donkey anti-sheep (for 
nephrin detection; 1:400), and Alexa Fluor 488 goat anti-mouse (for CD34 detection; 1:400). Rabbit anti-activated 
Caspase 3 antibody was used at a dilution of 1:500 (Fisher Scientific). Texas-Red® tagged 70 kDa dextran 
(Molecular Probes) was used for renal functional assays19. Proteinase K (10 mg/ml stock) was utilized for embryo 
digestion and linearized plasmid treatment (Roche Recombinant PCR grade). Zebrafish embryos were subjected 
to 300 μ M of the pancaspase inhibitor, zVAD-fmk (Sigma-Aldrich) incubation at 24 hpf for 24 hours.
CRISPR control, ELMO1 gRNA and Cas9 mRNA synthesis. ELMO1 gRNA: ELMO1-CRISPR-for#1: 
TAGGTGGCCATCGAGTGGCCTG (underlined region is the gRNA target site) and ELMO1-CRISPR-rev#1: 
AAACCAGGCCACTCGATGGCCACC, oligos were cloned into the plasmid, pUC19 (Addgene)29. BamHI-HF 
(Biolabs) was used for pUC19-linearisation. Cas9 mRNA was synthesised from pT3TS30 [Addgene] after line-
arising with XbaI (Biolabs). Plasmids were purified with the PCR purification kit (Qiagen). In vitro transcription 
was done by T7 MEGAshortscript kit (Invitrogen) (control and ELMO1 gRNA) and mMESSAGE MACHINE 
Kit (Invitrogen) (Cas9 mRNA). Purification of RNA after TURBO DNAse treatment was done via the MiRNeasy 
Mini (Qiagen) and RNeasy Mini (Qiagen) kits.
Morpholinos and mRNA. Morpholino oligonucleotides used were: SB-PDX1-Mo: 5′ -GATAGTAATGCT 
CTTCCCGATTCAT-3′ (targets the zebrafish PDX1 translation start site), and control-MO: 5′ -CCTCTTAC 
CTCAGTTACAATTTATA-3′ 31. Synthesis and injection of zebrafish ELMO1 and control mRNA were performed 
using the SP6 mMessage mMachine Kit (Ambion) as previously described13.
Injections of morpholinos, mRNA and gRNA. Morpholinos were diluted to 4 or 6 μ g/μ l in 0.1 M KCl. mRNA 
was diluted to 300 pg/nl; ELMO1 gRNA and Cas9 mRNA were diluted to 100 pg/nl and 150 pg/nl respectively, in 
0.1 M KCl. One nanoliter of morpholino or mRNA was injected into the embryos at the 1-cell stage.
Western blot analysis. Zebrafish embryos were collected at 48 hpf for Western blot analysis. Western blot was 
performed as described before32.
FACS sorting. 48 hpf Embryos of the Tg(wt1b:EGFP) were incubated in calcium free ringer solution (116 
mMNaCl, 2.9 mM KCl and 5 mM HEPES, pH 7.2), for 15 min. The embryos were then deyolked by rapid pipet-
ting, using a Gilson P200, washed with PBS, centrifugated (5 min, 1400 rpm). Embryos were digested for 20 min 
with 0.25% Trypsin in 1 mM EDTA (GIBCO), stopped with a stop solution (1x PBS, 10% FCS and 2 mM CaCl2). 
Embryos were resuspended in a FACS sorting buffer and passed through a 30 μ m filter (Partec Cell Trics). FACS 
analysis was performed by the Mannheim Cell Sorting Core Facility of the Medical Faculty, using a BD FACSAria. 
The GFP positive and negative cells were obtained in PBS, spun down and resuspended in RLT-Buffer with 
β -mercapthoethanol (Carl Roth GmbH). mRNA extraction was performed using the RNeasy Mini Kit (Qiagen). 
cDNA synthesis was carried out using the SuperScriptTM- First Strand Kit (Invitrogen).
Real-time quantitative PCR. Primer design for ELMO1 (target) and β -actin 1 (reference) for zebrafish was done 
by Roche Universal ProbeLibrary Assay Design Center. ELMO1: forward primer-5′ -‘gcaccatcaggatgcttaca-3′ ; 
reverse primer- 5′ -‘cggacactcatgtttatcctca’-3′ and that for β -actin 1: forward primer- 5′ -‘acggtcaggtcatcaccatc’-3′ 
and reverse primer- 5′ -‘tggataccgcaagattccat’-3′ . Probes #80 and #11 (Roche UPL) were used for ELMO1 and 
β -actin 1, respectively. 2x sentiFAST probe No-ROX mix (Bioline) was used in each 96-well reaction plate (Axon). 
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A Roche light cycler® 480 was used for the qPCR. Comparative ratio for ELMO1 expression was calculated with 
the 2-ddCP 33. The real-time quantitative PCR was repeated twice with a total of 6 replicates for each condition. The 
number of embryos used for the hyperglycaemic condition was 1017 and 895 for normoglycaemic conditions. 
The comparative ratio (Pfaffl formula) indicates no significant difference between ELMO1 expression levels.
Ultrafiltration assay. 72 hours post-fertilisation, 5 nl of Texas-Red® tagged 70 kDa dextran (2 ng/ml in PBS) was 
injected into the heart of tg(fli1:EGFP) embryos. Sequential images of the living fish were taken 1, 24 and 48 hours 
post injection (hpi) using an inverted microscope (Leica DMI 6000B) with a camera (Leica DFC420 C) and the 
Leica LAS application suite 3.8 software. Maximum fluorescence intensity in the heart area was measured using 
NIH’s ImageJ application (Supplementary Figure 3). The fluorescence values were compared in relative units of 
brightness for each fish.
Electron Microscopy (EM) study. Tg(wt1b:EGFP) embryos were injected at the 1-cell stage with control and 
PDX1 morpholinos (6 ng), control CRISPR gRNA/Cas9 mRNA (100 + 150 pg) and ELMO1 CRISPR gRNA/Cas9 
mRNA (100 + 150 pg). Embryos were fixed at 48 hpf in 0.01 Na-cacodylate buffer pH 7.4 for 24 h at 4 °C and sent 
for EM analysis.
Microscopy and analysis of pronephric alteration. For in vivo imaging Tg(wt1b:EGFP) embryos were embedded 
in 1% low melting point agarose (Promega), dissolved in E3 medium. Images were taken with a Leica DFC420 
C camera, attached to a Leica MZ10 F modular stereo microscope. Quantification of the pronephron was done 
using the Leica LAS V4.8 software. Imaging was carried out for TUNEL stained Tg(wt1b:EGFP) via a DMIRE2 
microscope with Leica TCS SP2 True Confocal Scanner and a DM6000 B microscope with Leica TCS SP5 DS 
scanner. Images were taken with 600 Hz, 1024 × 512 pixels and z-stacks were 1 μ m thick.
TUNEL assay. TUNEL assay was performed on 48 hpf Tg(wt1b:EGFP) embryos, using the ApopTag® Red 
In Situ Apoptosis Detection Kit (Millipore). The embryos were deyolked and fixed over-night at 4 °C, in freshly 
prepared 4% PFA/PBS. After washing in PBST (1x PBS/0.1% Tween-20), sequential dehydration with increas-
ing concentrations of methanol, was done to store them in 100% methanol overnight at − 20 °C. Embryos were 
rehydrated and treated with Proteinase K (10 μ g/ml, Roche) for 21 min. TUNEL protocol was hence followed as 
previously described14.
Activated Caspase 3 assay. 48 hpf aged Tg(wt1b:EGFP) embryos were deyolked and fixed over-night at 4 °C, 
in freshly prepared 4% PFA/PBS. After washing in PBST (1x PBS/0.1% Tween-20), sequential dehydration with 
increasing concentrations of methanol, was done to store them in 100% methanol overnight at − 20 °C. Embryos 
were rehydrated and washed (3x) in PBST for 20 min. After blocking for 1 hour at RT (Block buffer: 1x PBST, 
10% heat-inactivated fetal bovine serum, 2% bovine serum albumin), embryos were subject to an over-night 
incubation with rabbit anti-activated caspase 3 antibody (1:500) at 4 °C. After sequential washing with PBST and 
blocking for another hour, embryos were incubated with Alexa Fluor 546 goat anti-rabbit (1:400), over-night at 
4 °C. After washing 3x with PBST for 20 mins, embryos were thus prepared for examination under a confocal 
microscope.
Immunohistochemistry (IHC) and fluoro-IHC for ELMO1. Human kidney tissue samples were provided by the 
tissue bank of the National Center for Tumor Diseases (NCT, Heidelberg, Germany) in accordance with the reg-
ulations of the tissue bank and the approval of the ethics committee of Heidelberg University.
For IHC analysis 5 non-diabetic (2/3 male/female patients aged 39–71 years), diabetic (2/3 male/female 
patients aged 34–76 years) and polycystic kidneys (4/1 male/female patients aged 54–67 years) were analysed. 
All kidney organs were removed during organ recession between 2007–2015 for all patients. All diabetic patients 
suffered from long term type 2 diabetes and developed nephropathy where kidney function was reportedly dis-
rupted. Two diabetic patients showed other signs of diabetic complications such as retinopathy. All diabetic 
patients are assured to be insulin dependent. Sections of formalin-fixed, paraffin-embedded (FFPE) kidneys, 
provided by the NCT Tissue Bank, were cut at a thickness of 1 μ m (HM 340E Electronic Rotary Microtome, 
Thermo Scientific), dryed and stored at room temperature. IHC analysis was performed by using BenchMark 
ULTRA (Ventana Medical Systems). Antigens were retrieved with Protease 1 (12 min, room temperature, Ventana 
Medical Systems) and ELMO1 was detected with a polyclonal rabbit anti-ELMO1 antibody at 36 °C for 24 min-
utes, using the OptiView DAB IHC Detection Kit (Ventana Medical Systems). Podocin and CD34 were detected 
with their respective antibodies at 36 °C for 24 minutes, using the ultraView Universal Alkaline Phosphatase Red 
Detection Kit (Roche). NanoZoomer slide scanner (Hamamatsu) visualised tumor-free kidney parenchym and 
imaged with the Aperio ImageScope viewing software (Leica Biosystems, version 11.0.2.725).
For immunofluorescence staining, citrate buffer antigen revival method was used after de-paraffination was 
performed on kidney sections. After which, sections were blocked for an hour and incubated overnight at 4 °C 
with primary and then secondary antibodies. Fluorescent images were taken using a Zeiss Axio Imager D1 with 
a Axiocam mRm camera.
Quantification and statistics. TUNEL assay confocal images were processed using NIH’s ImageJ application. 
Apoptotic cell number/area was determined by the analyze particles tool of ImageJ, within the entire pronephric 
structure. Alterations in the pronephric structure were measured and quantified by measuring size in μ m of glo-
merular width and neck. Immunofluorescence staining analysis for ELMO1 expression in human kidney sections 
was carried out by measuring integrated density of the fluorescence value representing ELMO1 protein expres-
sion, via NIH’s ImageJ application. Background fluorescence was duly substracted and corresponding averages/
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group were compared using a student t-test. The number of patients analysed per group were 5 and 8 glomeruli 
and tubules taken from 4 different stained sections, was utilized for ELMO1 quantification. Statistical significance 
between different groups was analysed using Student’s t-test. Results are indicated as the mean value + /− SD. 
P-values < 0.05 were considered as significant *< 0.05, **< 0.01, and ***< 0.001.
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